CRTAC1

CRTAC1 is a secreted, glycosylated extracellular matrix protein originally defined as a chondrocyte marker distinguishing chondrocytes from osteoblasts and mesenchymal stem cells, and it localizes to the extracellular matrix of articular cartilage (PMID:17074475, PMID:11139377). High-resolution crystallography established its architecture as a compact three-domain β-propeller–TTR fold in which an extended TTR loop plugs the β-propeller core; the structure binds ten ions, with potassium ions wedged between propeller blades being essential for stability, such that potassium depletion exposes buried cysteines and promotes covalent intermolecular interactions and aggregation (PMID:39029889). The protein carries an N-terminal leader peptide, an EGF-like calcium-binding domain, FG-GAP repeat domains, an RGD integrin-binding motif, and a functionally O-glycosylated C-terminal exon, and its secretion by chondrocytes is induced by BMP4 (PMID:17074475, PMID:11139377). Functionally, CRTAC1 acts as a context-dependent regulator of cell signaling and survival across multiple cell types: it suppresses tumor progression in lung adenocarcinoma by blocking integrin/FAK signaling (PMID:41708954), enhances cisplatin-induced apoptosis in NSCLC by triggering ryanodine-receptor–mediated Ca²⁺ release that activates NFAT, induces STUB1, and accelerates Akt1 degradation (PMID:37633993), and inhibits proliferation, migration, and EMT in bladder cancer by binding and downregulating YY1 to inactivate TGF-β signaling (PMID:34818994). In non-cancer contexts, CRTAC1 promotes ROS-dependent pyroptosis in UVB-irradiated lens epithelial cells (PMID:32838966), and secreted CRTAC1 from senescent synoviocytes binds NRF2 in chondrocytes to suppress SIRT3 transcription, promote FOXO3a acetylation, impair mitophagy, and drive mitochondrial dysfunction in osteoarthritis (PMID:41311393). Its own expression is epigenetically silenced in bladder carcinoma through lncRNA TPRG1-AS1–directed recruitment of DNMT3A to the CRTAC1 promoter (PMID:36410635).

1. 2001 Medium

   Established CRTAC1 (CEP-68) as a secreted, EGF-like calcium-binding-domain protein and a chondrocyte-specific marker, defining a new protein family and its baseline cell-type identity.

   Evidence Gene characterization, sequence analysis, and marker comparison across chondrocytes, osteoblasts, and mesenchymal stem cells

   PMID:11139377

   Open questions at the time

   • No structural model of the protein
   • Functional role beyond cell-type marker undefined
   • No interacting partners identified
2. 2006 Medium

   Localized CRTAC1-A to articular cartilage ECM, mapped a functional C-terminal O-glycosylation site, and showed BMP4-induced secretion, defining its secretory and post-translational biology.

   Evidence Serial C-terminal deletion mutants with O-glycosylation inhibitor, immunolocalization in cartilage, and BMP4 stimulation in cultured chondrocytes

   PMID:17074475

   Open questions at the time

   • Function of the RGD motif not tested
   • Role of FG-GAP repeats not defined
   • Binding partners in ECM unknown
3. 2010 Low

   Predicted the N-terminal region as a seven-bladed β-propeller related to integrin alpha chains, providing the first structural hypothesis linking CRTAC1 to integrin-type folds.

   Evidence Computational structural prediction, phylogenetic analysis, and database searches

   PMID:20171266

   Open questions at the time

   • Purely computational with no experimental validation
   • β-propeller fold not confirmed biochemically at this stage
   • Functional consequence of fold relationship unaddressed
4. 2020 Medium

   Placed CRTAC1 upstream of ROS in a pyroptosis pathway, the first demonstration of a cell-signaling function for the protein.

   Evidence siRNA knockdown and overexpression in human lens epithelial cells with pyroptosis-marker western blotting and ROS-inhibitor rescue under UVB

   PMID:32838966

   Open questions at the time

   • Molecular mechanism linking CRTAC1 to ROS generation unknown
   • No receptor or direct binding partner identified
   • Generalizability beyond lens epithelial cells untested
5. 2021 Medium

   Identified YY1 as a direct CRTAC1 partner and defined a tumor-suppressive axis in bladder cancer through YY1 downregulation and TGF-β inactivation.

   Evidence Reciprocal Co-IP, co-localization, ChIP, luciferase reporter, and functional proliferation/migration/invasion assays in bladder cancer cells

   PMID:34818994

   Open questions at the time

   • No independent replication of the CRTAC1-YY1 interaction
   • How a secreted ECM protein modulates a nuclear transcription factor mechanistically unclear
   • Direct binding interface not mapped
6. 2022 Medium

   Explained how CRTAC1 is silenced in cancer, showing epigenetic repression via lncRNA-directed promoter methylation.

   Evidence ChIP-qPCR, luciferase reporter, methylation analysis, and rescue/knockdown experiments in bladder carcinoma cells with in vivo model

   PMID:36410635

   Open questions at the time

   • Generalizability of this silencing mechanism to other tumors untested
   • Upstream signals controlling TPRG1-AS1 only partly defined
   • No structural detail of DNMT3A recruitment
7. 2023 Medium

   Defined a mechanistic chemosensitization pathway in NSCLC linking CRTAC1 to RyR-mediated Ca²⁺ release, NFAT, STUB1, and Akt1 degradation.

   Evidence Overexpression/knockdown, intracellular Ca²⁺ measurement, NFAT reporter, western blotting, and in vivo cisplatin tumor model

   PMID:37633993

   Open questions at the time

   • How CRTAC1 triggers RyR-mediated calcium release mechanistically unknown
   • Direct molecular partner upstream of Ca²⁺ flux unidentified
   • Single-lab pathway without independent confirmation
8. 2024 High

   Determined the high-resolution three-domain β-propeller–TTR structure and its dependence on potassium for stability, providing the definitive structural framework for CRTAC1.

   Evidence X-ray crystallography at 1.6 Å with cysteine mutagenesis and tryptophan fluorescence

   PMID:39029889

   Open questions at the time

   • Structural basis for partner binding (YY1, NRF2, integrins) not resolved
   • Physiological consequence of potassium-dependent cysteine exposure in vivo unknown
   • Role of bound calcium ions in function untested
9. 2024 Low

   Extended CRTAC1 functions to gastric cancer and to a ligament calcification cell-cell axis, broadening its disease contexts.

   Evidence siRNA knockdown with PI3K/AKT/mTOR pathway western blotting in gastric cancer cells; scRNA-seq and SCENIC inference of an SPP1-ATF3-CRTAC1/MGP/CLU axis in spinal ligaments

   PMID:39158018 PMID:39725632

   Open questions at the time

   • Gastric cancer findings rest on single knockdown without rescue
   • Ligament axis is largely computational with limited experimental follow-up
   • Direct mechanistic links remain unestablished
10. 2025 Medium

    Identified NRF2 as a direct CRTAC1 binding partner and defined a senescence-driven NRF2–SIRT3–FOXO3a–mitophagy axis driving chondrocyte dysfunction in osteoarthritis.

    Evidence scRNA-seq, in vitro CRTAC1-NRF2 binding assay, western blotting, SIRT3 conditional knockout, and intra-articular AAV-SIRT3 rescue in mice

    PMID:41311393

    Open questions at the time

    • Structural basis of CRTAC1-NRF2 binding unresolved
    • How extracellular CRTAC1 accesses intracellular NRF2 unclear
    • Single-lab mechanism without independent replication
11. 2026 Medium

    Demonstrated that CRTAC1 suppresses lung adenocarcinoma progression through integrin/FAK signaling, connecting its RGD/integrin-related features to tumor suppression.

    Evidence Overexpression/knockdown in LUAD cells with proliferation/migration/invasion assays, integrin/FAK western blotting, and in vivo tumor model

    PMID:41708954

    Open questions at the time

    • Direct CRTAC1-integrin binding not demonstrated
    • Role of the RGD motif in this signaling untested
    • Single-lab finding without independent confirmation

• It remains unknown how a single secreted ECM protein engages such mechanistically distinct intracellular targets (YY1, NRF2, RyR/Ca²⁺, integrin/FAK) and what unifying receptor or entry mechanism governs its context-dependent actions.
• No defined cell-surface receptor linking secreted CRTAC1 to intracellular signaling
• Structural interfaces for named partners not mapped
• Determinants of cell-type-specific (tumor-suppressive vs degenerative) outcomes unknown